Gilead To Pay Verily $90 Million To Probe Immune Cells
Gilead Sciences will pay up to $90 million over three years to Verily to run a suite of tests on the white blood cells of patients with rheumatoid arthritis, inflammatory bowel disease, and lupus in the hopes of identifying which patients respond to existing drugs.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:GILD NASDAQ:GOOG Source Type: news
More News: Arthritis | Inflammatory Bowel Disease | Lupus | Pharmaceuticals | Rheumatoid Arthritis | Rheumatology